The vaccine will be the first and only two-dose vaccine in the USA for the prevention of hepatitis B in adults, and the first new hepatitis B vaccine in the USA in over 25 years.
Browsing: Drug development
Lonza (Basel, Switzerland) announce the launch of four new services to expand their early phase biopharmaceutical drug development.
In this question our experts discuss what they consider to be the main bioanalytical challenges for biosimilar drug development.
For therapeutic drug development and monitoring, microsampling technology provides a breakthrough alternative
One useful way to think about volumetric absorptive microsampling (VAMS) technology is as the next generation of traditional dried blood spot (DBS) cards. It’s a simpler method that makes it easier to collect blood and prepare it for analysis. With minimal training, the microsampling process can be self-administered anywhere, through a procedure that is less difficult and generally less expensive than working with conventional venous blood. Other benefits include a more pleasant patient experience, which leads to greater adherence and compliance, and freer access to remote areas of the world.
Get access to this webinar on-demand! De-risking represents a relatively new but developing strategy designed…
Considerations for Ligand Binding Assay Platforms: how to choose the right platform to meet your drug development needs
Bioanalytical assays are essential in drug development. In recent years, many new technologies have emerged which offer scientists throughput, sensitivity, multiplexing, and the ability to better understand the data.
Envigo launches hepatotoxicity testing as part of wider integrated drug development de-risking program
Envigo announces the launch of an integrated program of in vitro technologies that help predict…
Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management
In this perspective the authors discuss the value and consequences, along with technical issues, associated with the implementation of multibiomarker panels into medical practices in the near future, either to complement or to replace currently used standards.
European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development
This report discusses EBF recommendations on the bioanalysis of biomarkers in drug development.
Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development
In this white paper recommendations for the use of immunoassay kits are provided. These recommendations aim to standardize and harmonize user practices, contributing to reliable biomarker data from commercial immunoassays, thus, enabling properly informed decisions during drug development.